

THE GERMAN CENTER FOR INFECTION RESEARCH

- Bernhard Nocht Institute for Tropical Medicine
- Bundeswehr Institute of Microbiology
- Federal Institute for Drugs and Medical Devices
- Friedrich-Loeffler-Institut
- German Cancer Research Center
- Giessen University
- Hannover Medical School
- Heidelberg University
- Heidelberg University Hospital
- Heinrich Pette Institute–Leibniz Institute for Experimental Virology
- Helmholtz Centre for Infection Research
- Helmholtz Zentrum München–German Research Center for Environmental Health
- Klinikum der Universität München
- Klinikum rechts der Isar der TU München
- Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures
- Ludwig-Maximilians-Universität München
- Max Planck Institute for Developmental Biology
- Mittelhessen University of Applied Sciences
- Paul-Ehrlich-Institut
- Philipps-Universität Marburg
- Research Center Borstel–Leibniz-Center for Medicine and Bioscience
- Robert Koch Institute
- Technische Universität Braunschweig
- Technische Universität München
- TWINCORE–Centre for Experimental and Clinical Infection Research
- Universität Hamburg
- Universität zu Lübeck
- University of Bonn
- University of Cologne
- University of Tübingen
- University of Veterinary Medicine Hannover, Foundation
- University Hospital Bonn
- University Hospital Cologne
- University Hospital Tübingen
- University Medical Center Hamburg-Eppendorf

CONTACT

DZIF e.V.

Dr. Timo Jäger
Managing Director


Inhoffenstraße 7
D-38124 Braunschweig

T +49 (0)531-6181-1152
F +49 (0)531-6181-1153

info@dzif.de
www.dzif.de



UNITED AGAINST INFECTIONS



THINKING GLOBALLY – ACTING COLLABORATIVELY

Over 500 doctors and scientists from 35 establishments collaborate at the German Center for Infection Research (DZIF), jointly developing new approaches to prevent, diagnose and treat infectious diseases. This synergistic alliance of universities, hospitals and research institutes has established a globally unique infrastructure—aiming to effectively translate research results from bench to bedside, and vice versa: applying insights from clinical practice to research.

DZG DEUTSCHE ZENTREN
DER GESUNDHEITSFORSCHUNG



FUNDED BY

Bundesministerium
für Bildung
und Forschung




CHALLENGES IN INFECTION RESEARCH

Infectious diseases are a leading cause of death worldwide. Current problems such as antibiotic resistance, emerging viruses and bacteria, as well as the rapid spread of pathogens across national borders present physicians with new challenges. The World Health Organisation's figures speak for themselves:

- Approximately 10.4 million people contracted tuberculosis in 2015.
- In 2015, around 212 million new cases of malaria were registered, with 429,000 deaths.
- At the end of 2015, approximately 36.7 million people were living with HIV worldwide, and 2.1 million people newly contracted the disease in that year.
- 400 million people suffer from chronic viral hepatitis.
- Half the world's population carries the gastric pathogen *Helicobacter pylori*: it can cause gastric ulcers and gastric cancer.
- According to Robert Koch Institute estimates, several hundred thousand patients get infected with so-called hospital superbugs in Germany alone every year – with up to 15,000 deaths.

RESEARCH AREAS AND INFRASTRUCTURES



TRANSLATION: GETTING TO NEW DRUGS FASTER

The DZIF's fundamental goal is to more rapidly translate laboratory findings into new drugs, vaccines and diagnostics, and to use knowledge from clinical practice for research. Close collaborations between scientists, doctors, trial participants and patients, as well as a continuous multi-directional exchange of information, help to avoid costly wrong decisions.



COLLABORATING INTERNATIONALLY

Taking up global challenges in infection research calls for international collaborations. From the start, the DZIF has been strengthening collaborations with partner institutions in Africa in order to investigate diseases like malaria, tuberculosis and HIV where they predominantly occur. Additionally, a hospital in Romania has been included in the network for tuberculosis research. The DZIF is working on HIV and hepatitis together with the French institute INSERM (*Institut National de la santé et de la recherche médicale*). Furthermore, the DZIF is one of nine founding organisations of CARA (*Conscience of Antimicrobial Resistance Accountability*): an international alliance that aims to ensure that effective antibiotics will also be globally available in future. Beyond this, the DZIF is involved in the newly founded vaccine initiative CEPI (*Coalition for Epidemic Preparedness Innovations*). CEPI aims to develop vaccines that can be used immediately in the event of an emergency, following the experiences made with Ebola, Zika and MERS.